ERIS Lifesciences Ltd Share Price

Q: What is the share price of ERIS Lifesciences Ltd today?

ERIS Lifesciences Ltd share price as on 22 Jan 2025 is ₹1237.6

Pharmaceuticals - Indian - Formulations

NSE: ERIS Small Cap ISIN: INE406M01024

As on 22 January 2025 at 15:43 IST

₹1,237.60

-28.70

(-2.27%)

Sell Buy

About ERIS Lifesciences Ltd

Eris Lifesciences Ltd is a prominent Indian pharmaceutical company. The company operates in the pharmaceutical sector, specifically in branded formulations. It was founded in 2007 and has been in business for many years. The headquarters of Eris Lifesciences is located in the city of Ahmedabad in Gujarat. The company offers a variety of products, including medications for hypertension, diabetes, metabolic disorders, and other therapeutic areas. Their product portfolio also includes capsules and sachets. Eris Lifesciences Ltd’s commitment to innovation and quality has established it as a trusted name in the healthcare sector. Read More...

Over 1 Month

-5.26%

Over 6 Months

24.76%

Over 1 Year

43.90%

Over 3 Years

72.38%

ERIS Lifesciences Ltd Summary

Close ₹ 1,237.60

Open ₹ 1,258.15

High ₹ 1,267.05

Low ₹ 1,225.65

Volume 1,14,212

Net Turnover (in ₹) ₹ 1,98,66,190.65

52Wk High ₹ 1,593.90

52Wk Low ₹ 809.15

52Wk High / Low

809.15

1,593.90

ERIS Lifesciences Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 17,238.05

EPS (TTM) 8.54

Book Value (BV) 189.30

Div. Yield -

P/E (TTM) 148.04

Price/Book Value 6.68

Delivery % 34.93 %

Face Value 1

Key Ratios

PE Ratio 38.18

PB Ratio 4.53

EV to Sales 8.29

PEG Ratio -1.54

ROA 5.84

ROE 12.63

Debt-Equity 0.60

Net Profit Margin 19.61

Operating Profit Margin 31.97

ERIS Lifesciences Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	2,032.96	1,696.30	1,373.14	1,220.57	1,089.45
Total Expenses	1,601.72	1,291.66	930.94	826.07	758.11
Profit Before Tax	431.24	404.64	442.20	394.50	331.35
Profit After Tax	397.05	374.16	405.79	355.13	296.51
Operating Profit after Depreciation	516.04	430.81	446.34	396.30	333.51

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	4,328.14	2,568.45	920.92	855.43	879.22
Total Non Current Assets	4,746.76	2,902.61	1,644.81	1,367.73	1,072.69
Total Current Assets	2,302.07	764.72	627.33	467.05	479.62
TOTAL ASSETS	7,048.84	3,667.33	2,272.14	1,834.78	1,552.31
Total Shareholder's Fund	2,586.12	2,195.99	1,908.31	1,576.42	1,296.33

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	486.01	291.74	378.26	375.36	271.17
Net Cash used in Investing Activities	-1,827.56	-974.61	-319.61	-323.36	123.23
Net Cash used in Financing Activities	1,379.78	688.03	-44.70	-82.40	-334.59

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	1,521.53	1,347.99	1,244.72	1,118.83	1,034.96
Total Expenses	1,192.70	911.08	786.18	729.94	711.37
Profit Before Tax	328.83	436.91	458.54	388.89	323.59
Profit After Tax	299.71	398.01	417.19	350.61	291.27
Operating Profit after Depreciation	386.25	457.72	461.53	389.67	325.45

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	1,516.17	898.16	644.99	585.88	605.01
Total Non Current Assets	3,473.02	2,231.58	1,570.41	1,331.17	1,033.53
Total Current Assets	1,876.55	552.08	580.01	423.63	449.60
TOTAL ASSETS	5,349.57	2,783.66	2,150.42	1,754.80	1,483.13
Total Shareholder's Fund	2,524.02	2,221.88	1,918.56	1,575.47	1,299.70

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	336.29	322.33	369.41	395.41	265.25
Net Cash used in Investing Activities	-2,491.89	-513.30	-267.64	-347.86	126.74
Net Cash used in Financing Activities	2,160.06	193.75	-88.42	-81.13	-333.52

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	741.17	719.72	550.93	486.30	505.30
Total Expenses	476.66	469.73	402.50	310.78	324.16
Profit Before Tax	129.11	115.32	76.65	115.88	126.23
Profit After Tax	96.35	89.42	79.63	101.46	122.31
Operating Profit after Depreciation	269.06	251.63	163.58	179.72	184.62

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	436.56	456.69	341.30	324.41	409.71
Total Expenses	293.93	333.31	261.91	249.98	265.22
Profit Before Tax	46.02	26.82	41.75	34.64	119.92
Profit After Tax	28.10	17.04	39.51	31.66	117.81
Operating Profit after Depreciation	148.44	128.54	99.78	77.86	151.47

ERIS Lifesciences Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 1,252.23

S2 1,238.17

S3 1,220.78

Pivot 1,269.62

R1 1,283.68

R2 1,301.07

R3 1,315.13

Moving Average

20 SMA 1,308.84

50 SMA 1,374.99

100 SMA 1,366.06

200 SMA 1,182.48

ERIS Lifesciences Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

No available data

AGM Date: 01 Sep 2022

AGM 01/09/2022 In accordance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Register of Members and Share Transfer Books of the Company will be closed on Thursday, 25 August 2022 for the purpose of Sixteenth Annual General Meeting of the Company scheduled to be held on Thursday, 01 September 2022. Kindly take the above information on your records (As per BSE Announcement Dated on 05/08/2022) In accordance with the provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the copy of newspaper advertisement regarding the Notice of Sixteenth Annual General Meeting, remote E-voting and Book closure information of the Company published in Financial Express (both English and Gujarati) on 06th August, 2022. (As Per BSE Announcement Dated on 06/08/2022) PROCEEDINGS OF 16TH ANNUAL GENERAL MEETING OF THE COMPANY HELD ON 1ST SEPTEMBER 2022 (As per BSE Announcement Dated on 1/9/2022) SUBMISSION OF SCRUTINIZER'S CONSOLIDATED REPORT OF REMOTE E-VOTING AND E-VOTING CONDUCTED DURING THE AGM (As Per BSE Announcement dated on 02.09.2022) Eris Lifesciences Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As per BSE Announcement Dated on 3/9/2022)

AGM Date: 25 Sep 2023

Dear Sir/Madam, Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company, in their meeting held today, i.e., August 07, 2023, inter alia, duly approved/took on record the following: Convening of 17th Annual General Meeting of the Members of the Company on Monday, September 25, 2023. 17th Annual General Meeting of the Company is scheduled on 25th September 2023 at 11 AM through video conferencing (VC) Book Closure for annual General Meeting In accordance with Regulation 42 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Register of Members and Share Transfer Books of the Company will be closed on Monday, September 18, 2023, for the purpose of Seventeenth Annual General Meeting of the Company scheduled to be held on Monday, September 25, 2023. (As Per BSE Announcement Dated on 02.09.2023) Scrutinizer''s Report (As Per BSE Announcement Dated on 26.09.2023)

AGM Date: 25 Sep 2024

AGM 25/09/2024 Proceedings of 18th Annual General Meeting (As Per BSE Announcement dated on 25.09.2024) Scrutinizer''s Report for the 18th AGM held on September 25, 2024 (As Per Bse Announcement Dated on 26.09.2024)

ERIS Lifesciences Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
ERIS Lifesciences Ltd	₹1,264.30	₹17,210.82
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

ERIS Lifesciences Ltd News

Board of Eris Lifesciences approves acquisition of 30% stake in Levim Lifetech

At meeting held on 25 October 2024

25 Oct 2024, 06:47 pm

ERIS Lifesciences announces board meeting date

On 25 October 2024

22 Oct 2024, 03:56 pm

ERIS Lifesciences to convene AGM

On 25 September 2024

05 Aug 2024, 06:42 pm

ERIS Lifesciences announces board meeting date

On 2 August 2024

31 Jul 2024, 12:40 pm

Eris Lifesciences allots 22,492 equity shares under ESOP

24 Jun 2024, 12:26 pm

ERIS Lifesciences Ltd Stock Analysis

Annual revenue for ERIS Lifesciences Ltd increased by 12.87% to ₹1,521.53 crore in FY 2024 from ₹1,347.99 crore in FY 2023.
Annual Net Profit for ERIS Lifesciences Ltd decreased by 24.70% to ₹299.71 crore in FY 2024 from ₹398.01 crore in FY 2023.
Promoter Shareholding in ERIS Lifesciences Ltd decreased by 0.02% in the most recent quarter, from 54.87% in September 2024 to 54.86% in December 2024.
ERIS Lifesciences Ltd delivered a 1-year return of 43.90% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
ERIS Lifesciences Ltd share price moved down by 2.27% from its previous close of INR ₹1,266.30. The latest ERIS Lifesciences Ltd share price is INR ₹1,237.60.
ERIS Lifesciences Ltd share price today has been at a low of 1,225.65 and a high of 1,267.05. Over the past 52 weeks, the ERIS Lifesciences Ltd share price has seen a low of 809.15 and a high of 1,593.90.

About ERIS Lifesciences Ltd

Eris Lifesciences Ltd is a prominent Indian pharmaceutical company that develops pharmaceutical formulations. The company focuses mainly on chronic and sub-chronic diseases. It offers a diverse range of products in the cardio-metabolic and nephrology segments.

Eris Lifesciences operates in the pharmaceutical sector, specifically within the branded formulations market. Founded in 2007, Eris Lifesciences has been in business for many years. The company’s headquarters is located in Ahmedabad, Gujarat, India. The key promoters of Eris Lifesciences include Amit Bakshi, with a 42.87% stake in the company. He is also the Chairman and Managing Director. Apart from him, a team of professional managerial promoters manages the daily operations of the company. They are

Krishnakumar Vaidyanathan
Inderjeet Singh Negi
Kaushal Shah
Rajeev Dalal

Eris Lifesciences offers a variety of products. These include medications for hypertension, diabetes, metabolic disorders, and other therapeutic areas. Their product portfolio includes capsules and sachets. While Eris Lifesciences is a leading player in its sector, it is not currently ranked as the #1 stock in the pharmaceutical sector.

Eris Lifesciences holds a significant position in the Indian pharmaceutical market, particularly in the cardio-metabolic segment. However, it is not the most significant player in terms of market share or market capitalization. The promoters hold a substantial share in the company, ensuring strong leadership in the company.

The registered office of Eris Lifesciences is in Ahmedabad, Gujarat and the office of the registrars is in Mumbai, Maharashtra. The company continues to make significant strides in the pharmaceutical industry. It also focuses on improving patient care and expanding its product offerings to address chronic and lifestyle-related diseases. Its commitment to innovation and quality has made it a trusted name in the healthcare sector.

Vision of Eris Lifesciences Limited

Eris Lifesciences Ltd envisions making a significant impact in managing chronic lifestyle-related diseases. It aims to improve patient outcomes through innovative and high-quality pharmaceutical products. The company’s vision fuels its dedication to addressing the healthcare needs of patients with chronic conditions. This includes a strong focus on diabetes and cardiovascular diseases.

Eris Lifesciences has a strong emphasis on research and development. The company invests in cutting-edge technologies to stay at the forefront of innovation. It also focuses on scientific research to develop new and improved formulations. Their R&D efforts aim to create better efficacy and patient compliance medications. This focus on innovation ensures they stay ahead in the competitive pharmaceutical market.

The company places a high value on collaboration. Eris Lifesciences works closely with healthcare professionals to ensure its products meet industry needs. The company also engages with other stakeholders to address the evolving demands of the healthcare sector. These collaborations help them gain insights into the latest medical advancements and incorporate them into product development.

Eris Lifesciences is committed to maintaining the highest quality standards in all its products. The company adheres to stringent quality control measures at every stage of the manufacturing process. This commitment to quality ensures that their products are safe and effective for patients. It also helps build trust and credibility with healthcare providers and patients.

The company’s vision extends beyond just providing medications. Eris Lifesciences aims to be a holistic healthcare provider. It offers various patient care initiatives and support programs that help patients manage their conditions better. These initiatives include educational programs and patient support groups. Such efforts demonstrate their dedication to improving overall patient well-being.

Eris Lifesciences also focuses on sustainability and social responsibility. The company is committed to conducting its business in an environmentally responsible manner. It implements eco-friendly practices in its manufacturing processes to minimise its environmental footprint. Additionally, Eris Lifesciences engages in various social initiatives to improve community health and well-being.

The company’s vision is also reflected in its growth strategy. Eris Lifesciences aims to expand its presence in both domestic and international markets. It seeks to achieve this through strategic acquisitions and by entering new therapeutic areas. This growth strategy is aligned with its vision of making a broader impact on global healthcare.

Eris Lifesciences believes in the continuous development of its workforce. The company invests in training and development programs for its employees. These programs are designed to enhance their skills and knowledge. A motivated and skilled workforce is a crucial driver of their success.

The company’s leadership plays a crucial role in driving its vision. The promoters and management team are committed to upholding the company’s values and guiding it towards achieving its goals. Their strategic direction and decision-making align with the company’s vision of improving patient care and positively impacting healthcare.

Eris Lifesciences also emphasises the importance of ethical business practices. The company operates with integrity and transparency in all its dealings. This ethical approach helps build strong relationships with stakeholders and fosters a culture of trust.

The company’s vision is business growth and making a meaningful difference in patients' lives. Eris Lifesciences is dedicated to creating a healthier future for all. Its efforts are focused on providing innovative healthcare solutions that improve patient outcomes and enhance the quality of life.